5 completed, 3 active not recruiting, 1 withdrawn. 4 Early Phase 1, 3 Phase 1, 3 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 4 | Completed 3, Active not recruiting 1 |
| Phase 1 | 3 | Active not recruiting 2, Completed 1 |
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
| Not applicable | 1 | Withdrawn 1 |
Follow Stage III Fallopian Tube Cancer AJCC v7: new trials by email Literature Review of Stage III Fallopian Tube Cancer AJCC v7 trials Research Report on Stage III Fallopian Tube Cancer AJCC v7
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Carboplatin, Paclitaxel, Ruxolitinib Phosphate - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 / Phase 2 | Completed | NRG Oncology | 147 | 2016-11-14 | 2025-05-25 |
| Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer Internet-Based Intervention, Quality-of-Life Assessment, Questionnaire Administration - Endometrial Carcinoma, Stage 0 Fallopian Tube Cancer AJCC v7 | Not applicable | Withdrawn | Rutgers, The State University of New Jersey | 2016-07-27 | 2021-04-19 | |
| Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) Carboplatin, Durvalumab, Laboratory Biomarker Analysis - Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7 | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 18 | 2016-07-06 | 2026-06-11 |
| Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Carboplatin, Laboratory Biomarker Analysis, Paclitaxel - Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7 | Phase 2 | Completed | M.D. Anderson Cancer Center | 31 | 2016-07-05 | 2026-07-07 |
| Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Adavosertib, Laboratory Biomarker Analysis - Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma | Early Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 38 | 2016-02-04 | 2026-10-06 |
| Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Laboratory Biomarker Analysis, BMN 673 - Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma | Early Phase 1 | Completed | M.D. Anderson Cancer Center | 4 | 2015-06-02 | 2022-02-24 |
| Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Epacadostat, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery - Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7 | Early Phase 1 | Completed | National Cancer Institute (NCI) | 17 | 2014-08-25 | 2024-12-13 |
| Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer Carboplatin, Cisplatin, Gemcitabine Hydrochloride - FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer | Phase 1 | Active not recruiting | City of Hope Medical Center | 40 | 2014-05-19 | 2026-03-05 |
| Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Chemotherapy, Propranolol Hydrochloride, Quality-of-Life Assessment - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Early Phase 1 | Completed | M.D. Anderson Cancer Center | 32 | 2012-03-09 | 2019-08-29 |
Fallopian Tube Neoplasms (9) · Carcinoma (1) · Endometrial Neoplasms (1) · Ovarian Neoplasms (1) · Uterine Cervical Neoplasms (1)
Adnexal Diseases (9) · Fallopian Tube Diseases (9) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Genital Diseases (9) · Genital Diseases, Female (9) · Genital Neoplasms, Female (9) · Neoplasms (9) · Neoplasms by Site (9) · Urogenital Diseases (9) · Urogenital Neoplasms (9) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Gonadal Disorders (1) · Neoplasms by Histologic Type (1)
Carboplatin (4) · Paclitaxel (4) · Taxes (4) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Cisplatin (1) · Disulfides (1) · Doxorubicin (1) · Drug Therapy (1) · Gemcitabine (1) · Immunoglobulin G (1) · Platinum (1) · Propranolol (1) · adavosertib (1) · durvalumab (1) · epacadostat (1)
M.D. Anderson Cancer Center (5) · City of Hope Medical Center (1) · NRG Oncology (1) · National Cancer Institute (NCI) (1) · Rutgers, The State University of New Jersey (1)
United States (9)
Shannon N Westin (2) · Amir Jazaeri, MD (1) · Charles N Landen (1) · Kunle Odunsi (1) · Lois M Ramondetta (1) · Shannon Westin (1) · Sharon Manne (1) · Thanh Dellinger (1)
PMID 32379297, PMID 35357903, PMID 38776484, PMID 39151421
P30CA016672 (2), P30CA015704 (1), P30CA072720 (1), P50CA083639 (1), U01CA154967 (1), U10CA180868 (1)